Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Study Objectives: The association between obstructive sleep apnea (OSA) and liver fibrosis has been primarily evaluated using noninvasive tools or in selected populations (bariatric surgery). The aim of the study was to determine whether OSA is associated with liver fibrosis in patients with suspected nonalcoholic fatty liver disease (NAFLD) referred for liver biopsy.

Methods: Patients who underwent percutaneous liver biopsy for suspected NAFLD were prospectively included and investigated by in-lab polysomnography. Liver lesions were evaluated using the NASH-CRN scoring system and advanced fibrosis was defined as F ≥ 3. Moderate to severe OSA was defined by an apnoea-hypopnoea index (AHI) ≥15 events/h.

Results: Among the 97 patients included in the study, 40 exhibited advanced fibrosis, while 63 demonstrated moderate to severe OSA. The prevalence of moderate to severe OSA in patients with advanced fibrosis was 82% versus 52% in patients with F0-2 fibrosis stage (p<.0037). The association between moderate to severe OSA and advanced fibrosis remained significant after adjustment for sex, age, diabetes and obesity with an OR of 3.48 (confidence interval, 1.03-11.83; p=.045). Similar association was found with nocturnal hypoxia markers (oxygen desaturation index and the time spent under 90% of saturation). No association was observed between moderate to severe OSA and steatosis or nonalcoholic steatohepatitis.

Conclusions: Utilizing the gold-standard tools for OSA and NAFLD diagnosis in a multicentric cohort of biopsy-proven NAFLD patients, an independent association between OSA and liver fibrosis was confirmed.

Download full-text PDF

Source
http://dx.doi.org/10.1093/sleep/zsaf265DOI Listing

Publication Analysis

Top Keywords

liver fibrosis
12
advanced fibrosis
12
moderate severe
12
severe osa
12
association obstructive
8
obstructive sleep
8
liver
8
fibrosis patients
8
patients suspected
8
suspected nonalcoholic
8

Similar Publications

Bevacizumab for refractory gastrointestinal angiodysplasia: a case report and literature review.

Eur J Gastroenterol Hepatol

August 2025

Department of Gastroenterology and Hepatology, Noordwest Ziekenhuisgroep, Alkmaar.

Currently, symptomatic gastrointestinal (GI) angiodysplasia is treated with argon plasma coagulation (APC) via endoscopic procedures, supplemented with octreotide or thalidomide treatment. However, suboptimal response and side effects are often seen. Bevacizumab, an angiogenesis inhibitor, may provide an alternative systemic therapy for patients with refractory GI angiodysplasia.

View Article and Find Full Text PDF

Predicting Unplanned Readmission Risk in Patients With Cirrhosis: Complication-Aware Dynamic Classifier Selection Approach.

JMIR Med Inform

September 2025

College of Medical Informatics, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China, 86 13500303273.

Background: Cirrhosis is a leading cause of noncancer deaths in gastrointestinal diseases, resulting in high hospitalization and readmission rates. Early identification of high-risk patients is vital for proactive interventions and improving health care outcomes. However, the quality and integrity of real-world electronic health records (EHRs) limit their utility in developing risk assessment tools.

View Article and Find Full Text PDF

Objective: To verify the effect of physical exercise on the quality of life of patients with liver cirrhosis (LC).

Methods: the sample included controlled and randomized experimental studies of individuals with LC, at any stage of the disease, over 18 years of age, of both sexes, who performed any type of physical exercise compared to any other intervention or no intervention, with quality of life as the outcome assessed by the Chronic Liver Disease Questionnaire (CLDQ). The search for articles was conducted in 11 databases.

View Article and Find Full Text PDF